Pharma Sector

The Indian stock market extended its winning streak on June 17, 2026, as Nifty closed above the crucial 24,000 mark and Sensex gained 347 points. Defence stocks emerged as top performers following record domestic defence production in FY26, while lower crude oil prices, hopes of a US-Iran peace deal, and positive global cues supported broad-based buying across sectors.

Dr. Lal Path Labs surged to a fresh 52-week high after announcing its Dubai subsidiary and strong FY27 guidance. Robust earnings, steady demand in diagnostics, and long-term growth optimism supported investor sentiment.

Indian benchmark indices extended their rally on June 16, 2026, as optimism over US-Iran peace talks, lower crude oil prices, and FII buying lifted sentiment. Nifty and Sensex closed higher, with gains led by IT, Realty, FMCG, and Chemicals, while Metal and Auto lagged.

The Indian benchmark indices ended lower on June 11, 2026, with Nifty slipping to 23,161 and Sensex declining 150 points to close at 73,832, as a sharp selloff in IT stocks, fresh US-Iran escalation, and rising crude oil prices kept investor sentiment cautious through the session. Iran's declaration that the ceasefire had become "practically meaningless" rattled global markets, while weakness in AI-related stocks on Wall Street triggered broad selling in domestic technology counters. Nifty Bank managed a marginal gain of 76 points, with Media, Pharma, and Private Banks offering the only pockets of resilience in an otherwise weak session.

Indian benchmark indices ended on a mixed note on June 10, 2026, as geopolitical tensions, rising crude oil prices, rupee weakness, and persistent FII selling kept investors cautious. While FMCG and Private Bank stocks provided support, sectors such as Energy, Metals, Realty, and Media witnessed significant selling pressure ahead of key US inflation data.

The Indian stock market staged a strong recovery on June 9, 2026, as Nifty climbed 119 points and Sensex gained 394 points. Banking stocks surged following RBI's concessional FCNR(B) and ECB swap facilities, while lower crude oil prices, positive global market sentiment, progress in the India-US trade deal, and aviation sector tailwinds supported broad-based buying across Dalal Street.

SBI is considering a $1 billion commitment to help finance Sun Pharma’s proposed $12 billion acquisition of Organon. If approved, the deal would mark a major shift in Indian banks’ role in M&A financing following recent RBI regulatory reforms.

Hexagon Nutrition IPO attracted robust investor interest, with the issue subscribed 38.01 times on Day 3. The NII segment saw the highest demand, while retail investors subscribed 21.75 times. However, the GMP declined sharply from ₹12 to ₹3.5, suggesting a lower listing gain expectation despite strong subscription numbers.

Indian benchmark indices ended sharply lower on June 8, 2026, with Nifty closing at 23,123 and Sensex falling 719 points as geopolitical tensions between Iran and Israel, rising crude oil prices, weak global market sentiment, and US rate hike fears triggered a broad-based selloff across sectors.

Hexagon Nutrition IPO, a ₹138.87 crore book-built issue, opens for subscription from June 5 to June 9, 2026. The IPO is entirely an Offer for Sale (OFS), meaning the company will not receive any fresh capital. Backed by a diversified nutrition portfolio, export presence in over 75 countries, and improving profitability, the company offers exposure to India's growing nutrition and wellness sector. However, investors should consider customer concentration, dependence on the premix segment, and raw material price volatility before making an investment decision.